Suppression of excessive microglial overactivation can
prevent
the progression of multiple sclerosis (MS). Histone deacetylases 3
inhibitor (HDAC3i) has been demonstrated to exert anti-inflammatory
effects by suppressing microglia (M1-liked) activation. Here, we demonstrate
that the RGFP966 (a selective inhibitor of HDAC3) protects white matter
after cuprizone-induced demyelination, as shown by reductions in neurological
behavioral deficits and increases in myelin basic protein. Moreover,
in this study, we found that RGFP966 caused a significant reduction
in the levels of inflammatory cytokines, including IL-1β, TNF-α,
as well as iNOS, and inhibited microglial (M1-liked) activation in
the experimental cuprizone model and LPS-stimulated BV2 cells. Meanwhile,
RGFP966 alleviated apoptosis of LPS-induced BV2 cells in vitro. Furthermore,
RGFP966 suppressed the expression of P2X7R, NLRP3, ASC, IL-18, IL-1β,
and caspase-1, inhibited the ratio of phosphorylated-STAT3/STAT3 and
phosphorylated NF-κB p65/NF-κB p65, as well as increased
acetylated NF-κB p65 in vitro and in vivo. Furthermore, we confirmed
that brilliant blue G (antagonists of P2X7R) suppressed the expression
of microglial NLRP3, IL-18, IL-1β, caspase-1, NF-κB p65
(including phosphorylated NF-κB p65), and STAT3 (including phosphorylated
STAT3) in vitro. These findings demonstrated that RFFP966 alleviated
the inflammatory response and exerted a neuroprotective effect possibly
by modulating P2X7R/STAT3/NF-κB65/NLRP3 signaling pathways.
Thus, HDAD3 might be considered a promising intervention target for
neurodegenerative diseases, such as MS.